长链非编码RNA(lncRNA)因其在癌症发展中的致癌或抗肿瘤作用而众所周知。AGAP2-AS1,一种新的lncRNA,已被广泛证明是各种癌症中的致癌lncRNA。大量的实验结果证明AGAP2-AS1在大量恶性肿瘤中异常高水平,比如神经胶质瘤,结直肠,肺,卵巢,前列腺,乳房,胆管癌,膀胱,结肠癌和胰腺癌。重要的是,AGAP2-AS1的生物学功能已被广泛证明。它可以促进扩散,癌细胞的迁移和侵袭。同时,还说明了AGAP2-AS1的临床意义。AGAP2-AS1在各种癌组织中异常过度表达。临床研究表明,AGAP2-AS1的异常过表达与总生存期(OS)密切相关。淋巴结转移(LNM),临床分期,肿瘤浸润,高组织学分级(HG),浆液亚型和PFI时间。然而,到目前为止,AGAP2-AS1在人类癌症中的生物学作用和临床意义尚未得到系统评价。在本次审查中,作者概述了生物学行为,根据先前的研究,AGAP2-AS1的潜在机制和临床特征。总之,AGAP2-AS1,作为一个重要的致癌基因,是一个有前途的生物标志物和癌症预后和治疗的潜在靶点。
Long non-coding RNAs (lncRNAs) are well known for their oncogenic or anti-oncogenic roles in cancer development. AGAP2-AS1, a new lncRNA, has been extensively demonstrated as an oncogenic lncRNA in various cancers. Abundant experimental results have proved the aberrantly high level of AGAP2-AS1 in a great number of malignancies, such as glioma, colorectal, lung, ovarian, prostate, breast, cholangiocarcinoma, bladder, colon and pancreatic cancers. Importantly, the biological functions of AGAP2-AS1 have been extensively demonstrated. It could promote the proliferation, migration and invasion of cancer cells. Simultaneously, the clinical significances of AGAP2-AS1 were also illustrated. AGAP2-AS1 was exceptionally overexpressed in various cancer tissues. Clinical studies disclosed that the abnormal overexpression of AGAP2-AS1 was tightly connected with overall survival (OS), lymph nodes metastasis (LNM), clinical stage, tumor infiltration, high histological grade (HG), serous subtype and PFI times. However, to date, the biological actions and clinical significances of AGAP2-AS1 have not been systematically reviewed in human cancers. In the present review, the authors overviewed the biological actions, potential mechanisms and clinical features of AGAP2-AS1 according to the previous studies. In summary, AGAP2-AS1, as a vital oncogenic gene, is a promising biomarker and potential target for carcinoma prognosis and therapy.